The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer - PubMed (original) (raw)

Review

The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer

Mark J McKeage. Expert Opin Investig Drugs. 2008 Jan.

Abstract

5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a vascular disrupting agent that has demonstrated efficacy in combination with taxane-based chemotherapy in patients with advanced cancer. Complementary modes of action, a lack of pharmacokinetic interaction and distinct adverse effect profiles provide a strong rationale for combining these anticancer agents. In a Phase II trial in men with hormone refractory prostate cancer, DMXAA (ASA404) in combination with docetaxel achieved a prostate-specific antigen response in more patients than docetaxel therapy alone, and was generally well tolerated. Further clinical evaluation of this combination in this patient population is warranted.

PubMed Disclaimer

Similar articles

• Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.
  Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P. Pili R, et al. Clin Cancer Res. 2010 May 15;16(10):2906-14. doi: 10.1158/1078-0432.CCR-09-3026. Epub 2010 May 11. Clin Cancer Res. 2010. PMID: 20460477 Clinical Trial.
• Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m(2) combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer.
  McKeage MJ, Reck M, Jameson MB, Rosenthal MA, Gibbs D, Mainwaring PN, Freitag L, Sullivan R, Von Pawel J. McKeage MJ, et al. Lung Cancer. 2009 Aug;65(2):192-7. doi: 10.1016/j.lungcan.2009.03.027. Epub 2009 May 5. Lung Cancer. 2009. PMID: 19409645 Clinical Trial.
• The safety and tolerability of intravenous ASA404 when administered in combination with docetaxel (60 or 75 mg/m²) in Japanese patients with advanced or recurrent solid tumors.
  Daga H, Hida T, Ishikawa S, Shimizu J, Tokunaga S, Horio Y, Kobayashi K, Takeda K. Daga H, et al. Jpn J Clin Oncol. 2011 Sep;41(9):1067-73. doi: 10.1093/jjco/hyr110. Epub 2011 Aug 10. Jpn J Clin Oncol. 2011. PMID: 21835825 Clinical Trial.
• The evolving role of docetaxel in the management of androgen independent prostate cancer.
  Khan MA, Carducci M, Partin AW. Khan MA, et al. J Urol. 2003 Nov;170(5):1709-16. doi: 10.1097/01.ju.0000088787.95124.4b. J Urol. 2003. PMID: 14532760 Review.
• [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
  Wolff JM. Wolff JM. Onkologie. 2003 Dec;26 Suppl 7:37-40. doi: 10.1159/000076173. Onkologie. 2003. PMID: 14716141 Review. German.

Cited by

• Future directions in castrate-resistant prostate cancer therapy.
  Antonarakis ES, Carducci MA. Antonarakis ES, et al. Clin Genitourin Cancer. 2010 Dec 1;8(1):37-46. doi: 10.3816/CGC.2010.n.006. Clin Genitourin Cancer. 2010. PMID: 21208854 Free PMC article. Review.
• Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
  Antonarakis ES, Carducci MA, Eisenberger MA. Antonarakis ES, et al. Cancer Lett. 2010 May 1;291(1):1-13. doi: 10.1016/j.canlet.2009.08.012. Epub 2009 Aug 29. Cancer Lett. 2010. PMID: 19717225 Free PMC article. Review.
• Targeting angiogenesis for the treatment of prostate cancer.
  Antonarakis ES, Carducci MA. Antonarakis ES, et al. Expert Opin Ther Targets. 2012 Apr;16(4):365-76. doi: 10.1517/14728222.2012.668887. Epub 2012 Mar 13. Expert Opin Ther Targets. 2012. PMID: 22413953 Free PMC article. Review.
• Role of the STING pathway in myeloid neoplasms: a prospero-registered systematic review of principal hurdles of STING on the road to the clinical practice.
  Sampaio LR, Dias RDB, Goes JVC, de Melo RPM, de Paula Borges D, de Lima Melo MM, de Oliveira RTG, Ribeiro-Júnior HL, Magalhães SMM, Pinheiro RF. Sampaio LR, et al. Med Oncol. 2024 Apr 24;41(6):128. doi: 10.1007/s12032-024-02376-8. Med Oncol. 2024. PMID: 38656461 Review.
• 18F-fluromisonidazole PET imaging as a biomarker for the response to 5,6-dimethylxanthenone-4-acetic acid in colorectal xenograft tumors.
  Oehler C, O'Donoghue JA, Russell J, Zanzonico P, Lorenzen S, Ling CC, Carlin S. Oehler C, et al. J Nucl Med. 2011 Mar;52(3):437-44. doi: 10.2967/jnumed.110.081372. Epub 2011 Feb 14. J Nucl Med. 2011. PMID: 21321262 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Medical

  • MedlinePlus Health Information